

Prescribing Clinical Network

| | |
|---|--|
| Policy Statement | Xultophy (insulin degludec/liraglutide) in type II diabetes. |
| Policy No: | PCN 183 -2016 |
| Date of Issue | February 2016 |
| Review Date: | February 2019 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i> |
| Recommendations: The PCN does not recommend the use of Xultophy (insulin degludec/liraglutide) and it will be considered BLACK on the traffic light system | |
| Key Consideration: <ul style="list-style-type: none"> Limited published evidence (DUAL I, DUAL II) available. DUAL II, DUAL IV & DUAL V have not been published and expected results have yet to be confirmed. Degludec given BLACK status in August 2013 – insufficient evidence available to support use as a cost effective treatment option. Fixed dose combination product reduces flexibility in adjusting doses | |
| Date taken to Prescribing Clinical Network | February 2016 |
| Agreed by PCN members | 22 nd February 2016 |